Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines

Advanced hepatocarcinoma (HCC) is an aggressive malignancy with poor prognosis and limited treatment options. Alterations of the cyclin D-CDK4/6-Rb pathway occur frequently in HCC, providing the rationale for its targeting at least in a molecular subset of HCC. In a panel of HCC cell lines, we inves...

詳細記述

書誌詳細

主要な著者:	Graziana Digiacomo, Claudia Fumarola, Silvia La Monica, Mara A. Bonelli, Daniele Cretella, Roberta Alfieri, Andrea Cavazzoni, Maricla Galetti, Patrizia Bertolini, Gabriele Missale, Pier Giorgio Petronini
フォーマット:	Artigo
言語:	Inglês
出版事項:	Frontiers Media S.A. 2020-09-01
シリーズ:	Frontiers in Oncology
主題:	hepatocarcinoma (HCC) CDK4/6 inhibition palbociclib (PD-0332991) regorafenib metabolism
オンライン･アクセス:	https://www.frontiersin.org/article/10.3389/fonc.2020.563249/full
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!